[18F]FDG PET/CT as an endpoint marker in drug interventional studies in atherosclerosis - a structured review Authors: Casper E W Gijsen, Felix M Mottaghy, Ahmed Tawakol, Joachim E Wildberger, Jan Bucerius Published: 2026 ABSTRACT AbstractBackgroundInflammation plays a central role in the initiation, progression, and destabilization of atherosclerotic plaques. Persistent vascular inflammation despite therapeutic intervention may contribute substantially to residual cardiovascular risk. In this context, [18F]fluorodeoxyglucose-positron-emission-tomography ([18F]FDG PET) imaging has emerged as a non-invasive imaging biomarker capable of visualizing and quantifying vascular inflammatory activity in vivo. Previously published studies showed that the use of [18F]FDG PET may provide a non-invasive assessment of arterial inflammation. Accordingly, we aimed to systematically summarize treatment studies using [18F]FDG PET as an endpoint marker.Main body18 studies were considered to be eligible for data extraction. Of these 22 articles, 10 investigated vascular inflammation reduction after trials with lipid-lowering therapies, the other 12 were considering the effect of novel anti-inflammatory drugs on vascular inflammation.ConclusionThis review provides an overview of the additional value that [18F]FDG PET can provide as an endpoint marker in clinical intervention trials. Overall, statin therapies demonstrated a more consistent reduction in vascular [18F]FDG uptake compared to novel anti-inflammatory therapies.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s13550-026-01489-7.Keywords: [18F]FDG PET/CT, Atherosclerosis, Inflammation, Interventional Studies Background Atherosclerotic disease is initiated by vascular risk factors, promoting endothelial dysfunction, expression of adhesion molecules and binding of circulating inflammatory cells to the endothelium. This enables the arterial wall lesion to develop and to progress to become an atherosclerotic plaque [1]. So-called high-risk plaques are more vulnerable (prone) to rupture and are characterized by larger invasion of inflammatory cells, necrotic lipid core, microcalcifications, neovascularization and a thinning fibrous cap compared to low-risk plaques [1–4]. Accordingly, inflammation plays a crucial role in all stages of atherosclerotic plaque development and especially in the evolution from a stable plaque to an unstable plaque, which can, by rupturing, lead to clinical manifestations such as myocardial infarction and stroke [1, 5, 6]. Atherosclerosis is increasingly recognized as a chronic inflammatory disease rather than solely a lipid-storage disorder. Although lipid accumulation contributes to plaque formation, inflammatory activity within the arterial wall is considered a major determinant of plaque progression, destabilization, and ultimately cardiovascular events. Residual vascular inflammation may persist despite adequate lipid-lowering therapy and may therefore represent an integrated marker of ongoing cardiovascular risk. Consequently, imaging techniques capable of visualizing arterial inflammation have gained considerable interest in recent years. Lipid-lowering medications and acetylsalicylic acid (ASA) are considered fundamental therapies in the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD) [7]. First-line medication for this purpose are hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors (statins), which lower low-density lipoprotein (LDL) via inhibition of the de novo synthesis of cholesterol (primarily in the liver), and enhancing the expression of hepatic low-density lipoprotein cholesterol (LDL-C) receptors, thus resulting in a decrease of plasma LDL-C levels. As a result of this reduction in LDL-C, statins have pleiotropic effects leading to a reduction in atherosclerotic inflammation, and have a well-described impact on cardiovascular disease (CVD) risk [8]. Furthermore, statins display anti-inflammatory properties, characterized by a decrease in the release of C-reactive peptide (CRP), chemokines, cytokines, and adhesion molecules, along with the modulation of T-cell activity [9]. However, despite the substantial risk reduction stemming from lipid lowering therapies, the residual atherosclerotic disease risks remain high, often due to residual inflammatory risks [1, 10–12]. Thus, more direct anti-inflammatory treatments are being investigated resulting in a need for tools to assess their impacts on the blood vessel wall. Positron emission tomography (PET) is a functional imaging technique, which enables non-invasive molecular imaging of oncologic, neurologic, cardiovascular and infectious/inflammatory processes. Crucial advantages of this methodology include sensitive visualization of nano- to picomolar molecular or cellular processes, as well as quantitative assessment of radioactive tracer uptake related to those functional mechanisms [13, 14]. A more recent indication of quantitative PET imaging is the detection of inflammation in atherosclerotic arterial wall changes or atherosclerotic plaques with [18F]fluorodeoxyglucose PET ([18F]FDG). The uptake of this PET tracer in atherosclerosis imaging is based on the metabolic activity of, among other inflammatory cells, plaque macrophages, which avidly take up [18F]FDG (Fig. 1) [15, 16]. Overview of immune cell–driven vascular inflammation and [18F]FDG PET visualization in atherosclerosis Figure 1 illustrates the potential of [18F]FDG PET as a marker in interventional studies. As already mentioned above, [18F]FDG PET is capable of (directly) detecting vascular-specific inflammation. Here, molecular imaging is able to fill in gaps left open by for instance other (morphological) imaging modalities or blood biomarkers like e.g. high-sensitive (hs) - CRP, as its specific accumulation in the arterial wall as a marker of inflammation cannot only be visualized but also be quantified by standardized uptake values (SUV). Frequently, the arterial SUVs are corrected for the activity of the tracer in the venous blood pool, yielding a target to background ratio (TBR), which is assumed to provide a more reliable insight of the tracer uptake in the arterial wall [15]. Over the last decades, arterial [18F]FDG PET imaging has not only been evaluated in multiple studies regarding the diagnostic performance of inflammatory vessel wall changes within the atherosclerotic disease process, where it has been established as a reliable and sensitive diagnostic tool [14, 17]. [18F]FDG PET is not only applied to evaluate the effect of statins on vessel inflammation but has also been used for other anti-inflammatory drugs, such as canakinumab (an IL-1β inhibitor), methotrexate, and colchicine, which target systemic inflammation [18–22]. Previously published studies revealed that the use of [18F]FDG PET may provide a non-invasive, longitudinal follow-up of arterial inflammation after the administration of lipid-lowering/anti-inflammatory drugs in patients with increased cardiovascular risk [21, 23–25]. The aim of this review is to systematically review and to summarize the literature on [18F]FDG PET as an endpoint marker in cardiovascular interventional studies. Main text Study protocol This systematic review was written according to the guidelines provided by the Preferred Reporting System for Systematic Reviews and Meta-Analyses (PRISMA) statement for reporting systematic reviews [26]. Eligibility criteria Types of studies and outcome measures For this review, randomized controlled trials (RCTs) and non-randomized open-label studies were included that met the following criteria: (i) participants received statins or novel anti-inflammatory drugs in atherosclerosis (ii) studies reported any of the following outcomes: SUVs as well as TBRs (iii) the language of the study was restricted to English. No publication date was imposed. Animal/pre-clinical studies were excluded. Types of participants Only RCTs and open-label studies that compared the effectiveness of lipid-lowering and anti-inflammatory drugs during a period of at least three months. Studies including both male and female patients aged 18 years or older with a history of atherosclerosis were eligible for this systematic review. Information sources and search strategy The following database was accessed: PubMed. The search was performed by two authors via the PubMed database on the 15th of October 2025 in order to identify all studies on the effect of statins and anti-inflammatory drugs quantified by [18F]FDG PET. The following search contains the described terms in a free search as well as in a Medical Subject Headings (MeSH) search if possible: ((((((((((plaques) OR atherosclerotic plaques[MeSH Terms]) OR atherosclerotic plaque) OR plaques, atherosclerotic[MeSH Terms])) OR ((atherosclerosis) OR atherosclerosis[MeSH Terms]))) AND ((((Fluorodeoxyglucose F18) OR 18f fluorodeoxyglucose[MeSH Terms])) OR (((((FDG PET) OR 18 F FDG PET) OR f 18, fluorodeoxyglucose[MeSH Terms]) OR fluorodeoxyglucose, 18f[MeSH Terms]) OR fluorodeoxyglucose f18[MeSH Terms]))) AND ((humans) OR humans[MeSH Terms]))) AND ((randomized controlled trial[MeSH Terms]) OR randomized controlled trial) Detailed search queries are provided in Tables 1 and 2 of Appendix A. Bibliographies of relevant articles were also manually scanned for additional studies. Table 1Search strategies for PubMedMesh TermFree TermPatient + target diseasePlaques, atherosclerotic, atherosclerosis, humansAtherosclerotic plaque, plaques, atherosclerosis, humansInterventionFluorodeoxyglucose F18, fluorodeoxyglucose, 18f, fluorodeoxyglucose f18, randomized controlled trialFluorodeoxyglucose F18, FDG-PET, 18 F FDG-PET, f 18, fluorodeoxyglucose, randomized controlled trialTreatment--Outcome measure-- Search strategies for PubMed Table 2Inclusion and exclusion criteria regarding studiesInclusionExclusionStudy populationMale/female, ≥ 18 years of age, elevated risk on cardiovascular risk,< 18 years of agePurpose of interventionTo evaluate if the usage of lipid-lowering medication/anti-inflammatory drugs can reduce vascular inflammationOutcome measurementsStandard uptake values (SUV) and Target to background ratio (TBR) qualified by [18F]FDG-PETStudy DesignRandomized controlled trials, open-label non-randomizedRetrospective studies, reviews, Animal/pre-clinical studiesType of PublicationPeer reviewedLanguageEnglish languageOther Inclusion and exclusion criteria regarding studies Study selection Relevant outcomes were defined as measurements of arterial inflammation using [18F]FDG PET, including changes in SUV, TBR, and other quantification methods. The inclusion criteria encompassed studies evaluating the impact of interventions on arterial inflammation using these [18F]FDG PET-based inflammatory metrics. Studies were excluded if they lacked sufficient methodological detail or did not provide [18F]FDG PET measurements. The study selection process was performed by two authors independently, followed by a consensus meeting in cases of disagreement. Titles and abstracts were screened to assess alignment with the review objective. Full-text reading was conducted for potentially relevant studies after initial abstract screening. Exclusion criteria were as follows: non-English language studies, animal studies, other reviews, participants under 18 years of age, or studies not focusing on inflammation reduction using statins or anti-inflammatory medicines, thereby failing to meet the review’s objectives. Data collection process Data from the studies were summarized in a data extraction sheet. This sheet was constructed solely for this review. The authors of this review extracted the data. Data items The following information was extracted from the included studies: First author’s surname. publication year, study design, target population, scanning protocol, treatment duration, number and characteristics of the subjects, primary outcome measurements and outcomes regarding effects on biomarkers. This information was written down at the data sheet. Risk of bias in individual studies The methodological quality of the RCTs was assessed using the Cochrane risk-of-bias tool-2 (ROB-2), recommended by the Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 [27]. The open-label non-randomized studies were assessed using the Risk Of Bias In Non-Randomized Studies or Interventions (ROBINS-I) [28]. Summary measures The primary outcome measures were the reduction in vessel inflammation measured by [18F]FDG PET and quantified as standard uptake values corrected for the background, target to background ratio (TBR). Secondary parameters such as inflammatory parameters and lipid-profiles were evaluated. Synthesis of results Study outcome measures have not been modified since no meta-analysis had been performed. A qualitative analysis was carried out to synthesize the results of the included studies. Risk of bias across studies No assessment of risks across studies was performed. Additional analyses No additional analyses were executed. Results Study selection The PubMed database search identified 47 studies. An additional 4 studies were identified through references in other articles. After reading the titles, abstracts and full texts, 22 studies were eligible for data extraction. Of these 22 articles, 10 investigated vascular inflammation reduction after usage of lipid-lowering drugs, the other 12 were investigating the effect of novel anti-inflammatory drugs on vascular inflammation. Figure 4 of appendix B demonstrates the flow chart of the study selection. A flowchart of the study selection Study characteristics Appendix C summarizes the characteristics and the applied [18F]FDG PET imaging protocols (Tables 3 and 4) of the different studies considering vascular inflammation after cardiovascular interventions. Twenty of the included studies in this review were RCTs and two were prospective open-label studies. Table 3PET/CT Imaging Protocol and Data Analysis per Study Author Nutritional state (time of fasting prior to procedure) Glucose cut-off point at time of imaging Intravenous dosage of [18F]FDGDuration between injection of [18F]FDG and PET/CT scan (uptake period)Bissonnette et al. 2012 [54]Overnight fast<11 mmol/L370 MBq120 minBoczar et al., 2021 [40]Overnight fast<11 mmol/L5 MBq per kilogram of body weight120 minDe Boer et al., 2017 [57]Overnight fast of at least six hours<11 mmol/L3 MBq per kilogram of body weight60 minElkhawad et al., 2012 [25]At least six hours<11 mmol/L240 MBq90 minEmami et al., 2015 [24]At least four hours<200 mg/dL.370 MBq120 minFayad et al., 2011 [23]-<200 mg/dL-120 minGaztanaga et al., 2015 [49]Subjects followed a low-carbohydrate diet for 24 h prior to scanning.<200 mg/dL370 MBq120 minGelfand et al., 2020 [55]Overnight fast<150 mg/dL2.5–5.2 MBq of FDG per kilogram of body weight.120 minIshii et al., 2010 [41]At least eight hours-3.7 mBq per kilogram of body weight60 minJamialahmadi et al., 2022 [50]fasted for at least 4 h before PET/CT examination<160 mg/dL5.2 MBq per kilogram of body weight60 min Lo et al. 2015 [39]Overnight fast-418 MBq180 minMäki-Petäjä et al., 2012 [53]- - 250 MBq90 minMizoguchi et al. 2011 [60]At least a twelve-hour fasting-4.2 mBq per kilogram of body weight180 min Nitta et al. 2013 [59]At least a twelve-hour fasting-4.2 mBq per kilogram of body weight180 minOh et al., 2019 [42]At least eight hours<130 mg/dL5.2 MBq per kilogram of body weight120 minRipa et al., 2021 [58]At least six hours- 4 MBq per kilogram of body weight120 minSingh et al., 2016 [35]Overnight fast<200 mg/dL370 MBq90 minStiekema et al., 2018 [43]Overnight fast of at least six hours-240 MBq90 minTahara et al., 2006 [6]At least a twelve-hour fasting-4.2 mBq per kilogram of body weight60 minTawakol et al., 2013 [21]Overnight fast<200 mg/dL370 MBq120 minWatanabe et al., 2015 [20]At least eight hours-3.7 mBq per kilogram of body weight60 minWu et al., 2012 [19]At least eight hours<115 mg/dL333-407 mBq60 and 150 minMBq (megabecquerel) PET/CT Imaging Protocol and Data Analysis per Study Lo et al. 2015 [39] Nitta et al. 2013 [59] MBq (megabecquerel) Table 4Characteristics of the Included Studies Author Study design Included population Treatment duration N Study Groups Age (years) Male (n %) BMI (kg/m2) Total Cholesterol (mg/dL) LDL Cholesterol (mg/dL) HDL Cholesterol (mg/dL) Triglycerides (mg/dL) C-Reactive protein (mg/L) TBR index vessel Bissonnette et al. 2012 [54]Single-center, randomized controlled trialSubject with chronic, moderate, severe psoriasis4 months2010Adalimumab 40 mg/day,placebo56.05±10.9557.40±7.6017 (85)6 (60)NDND177.88±37.51180.97±44.08105.95±37.51109.82±33.2641.76±12.3740.60±8.1265.35±30.9490.10±66.514.22±3.664.28±2.65Ascending aorta1.86±0.352.04±0.51Carotid arteries1.65±0.251.84±0.29Boczar et al., 2021 [40]Single-center, randomized controlled trialHIV-infected patients6 months1718Rosuvastatin 10 mg/day, current medication50.5±6.552.3±7.912 (71)18 (100%)27.0±4.024.4±3.2ND45.2±0.7448.8±0.69NDNDNDThoracia aorta2.99 ±.452.99 ±.32De Boer et al., 2017 [57]Randomized controlled trial (double blind), The NetherlandsSubjects with type 2 diabetes6.5 months2119DPP-4 inhibitor linagliptin 5mg/dayplacebo63 (54-66)28(61)30.4 (27.5-35.8)184.45±36.7118.71±39.4452.98±12.3761.48±32.101.15 (0.70-3.08)Linagliptin2.12 [1.99-2.26]Placebo2.09 [1.96-2.21]Elkhawad et al., 2012 [25]Phase II, randomized, double-blind, placebo-controlled study, UKSubjects with a clinically stable history of atherosclerosis3 months343332losmapimod 7.5 mg twice daily, losmapimod 7.5 mg once daily,placebo62.3±5.9065.3±5.9463.7±6.3729282829.8±3.6828.0±3.3528.9±3.44143.24 (28.65)144.24 (28.76)150.97 (49.64)74.32 (23.63)77.61 (19.85)85.71 (25.79)44.79 (11.97)47.49 (12.39)47.49 (10.66)123.89 (45.04)129.20 (65.66)144.25 (49.65)1.30 (114)1.30 (146)1.00 (133)Index vesselHD2.07±0.31LD2.05±0.22Placebo1.94±0.24Emami et al., 2015 [24]Randomized, partially double-blinded study (double-blind), USSubjects with a history of atherosclerosis3 months242424BMS-582949 100 mg/day, Atorvastatin 80 mg/day, Placebo63.1±5.962.8±7.116 (66.7)18 (75.0)NDNDNDND92±1991±2453±1449±11NDND1.0(2.4)1.6(3.4)2.41±0.332.50±0.96Fayad et al., 2011 [23]Phase 2b, double blind, multicenter trial, RCT, USSubjects with high risk on CVD24 months6466Dalcetrapib tablet 600mg/day, placebo62.6 (8.2)64.6 (7.8)51 (80)55 (83)29.6 (4.8)29.8 (6.2)143.08 (27.06)146.95 (27.06)73.47 (23.20)73.47 (19.33)42.54 (11.60)46.40 (15.47)54.14 (38.67-73.47)58.00 (38.67-69.61)1.4 (0.6-3.7)1.4 (0.8-2.8)MDS2.7 (0.7)2.8 (0.7)Mean1.8 (0.4)1.9 (0.3)Gaztanaga et al., 2015 [49]Phase II, randomized, double blind, parallel-group study, USSubjects with acute coronary syndrome6 months2421VIA-2291, 100 mg/day, placebo56.6 (9.67)59.1 (7.20)23 (95.8)19 (90.5)29.6 (5.14)28.3 (3.90)154.0 (51.90)158.6 (47.94)83.5 (41.61)92.2 (36.56)41.6 (9.07)39.3 (8.90)137.0(110.46)135.2(64.39)NDMean of mean1.60±0.261.62±0.30MDS2.25±0.282.25±0.43Gelfand et al., 2020 [55]A randomized, double-blinded, placebo-controlled, parallel-group, multicenter studyadult patients (≥18 years of age) with moderate-to-severe chronic plaque psoriasis3 months4645Secukinumab 300 mg, Placebo47.9 (12.7)47.0 (14.7)33 (71.1)28 (62.2)31.09 (6.8)32.75 (7.8)NDNDNDNDNDNDIshii et al., 2010 [41]A Randomized, Investigator-Blinded, open-Label study, JapanJapanese adults with stable angina pectoris6 months1515Atorvastatin 5 mg/day, Atorvastatin 20 mg/day55±1053±118 (53.5)7 (46.7)NDND234±36244±25150±28162±2048±1447±13170±121189±811.0±0.61.4±0,9Ascending aorta1.11±0.101.15±0.14Femoral artery1.10±0.161.12±0.11Jamialahmadi et al., 2022 [50]a randomized, double-blind, placebo-controlled clinical trialAdults with a with history of myocardial infarction (MI) and percutaneous coronary intervention (PCI)3 months105Trehalose 15 gram IV weekly/placeboNDNDND115.00±40.00109.60±32.0864.69±31.1663.8±26.0934.40±6.9732.20±4.43117.00±72.56122.80±93.849.15 ± 3.848.14 ± 4.71Right carotid0.92 ± 0.270.81 ± 0.19Left carotid0.78 ± 0.200.82 ± 0.15Aorta1.20 ± 0.271.35 ± 0.26 Lo et al. 2015 [39]Randomized, double-blind, placebo-controlledHIV-infected patients12 months1921Atorvastatin40 mg/day,placebo52.2±3.750.0±5.615(79)17(81)25.6±2.925.8±4.8198.8±37.9192.2±27.1123.7±36.7124.9±32.151.8±19.350.7±15.1120.5 (97.4-204.6)113.4 (92.1-135.5)0.8 (0.3-1.9)1.1 (0.4-2.4)Aorta2.08±0.322.20±0.37Segment of aorta2.18±0.332.26±0.37Mäki-Petäjä et al., 2012 [53]Small, open-label study (non-randomized, with blinded endpoints), UKSubjects with Rheumatoid arthritis2 months17Anti-TNF-α therapy (12x adalimumab, 5x etanercept)58±56 (35)28.1±5.8208.82±34.80NDND50.27±23.2011.0 (4.0-29.0)RA2.02±0.22CVD1.74±0.22Mizoguchi et al. 2011 [60]Randomized, comparator-controlled trialSubjects with IGT and DM type 24 months3121Pioglitazone 15-30 mg/dayGlimepiride0.5-4 mg/day68.2±7.368.0±9.1221724.9±3.324.8±3.6NDND111±26119±2450±1251±13105 (85-131)121 (81-165)0.78 (0.37-2.07)0.72(0.41-1.51)Pioglitazone1.46±0.29Glimepiride1.35±0.26 Nitta et al. 2013 [59]Randomized, active comparator-controlled, single-center trialSubjects with IGT and DM type 24 months2522Pioglitazone 15-30 mg/dayGlimepiride0.5-4 mg/day68.8±7.267.3±9.31918NDNDNDND108.4±23.8117.6±24.849.9±12.851.3±13.0105.0 (79.5-125.5)120.0 (119.5-145.5)0,78 (0.34-1.93)120.0(74.8-164.0)Pioglitazone1.39±0.32Glimepiride1.45±0.29Oh et al., 2019 [42]Single center, randomized, open-label trial using a 2-by-2 factorial designSubjects with hypertension and ACS6 months2525Ezetimibe/simvastatin 10/10 mg versus rosuvastatin 10 mg62.5±7.459.2±8.82221NDND174.2±38.90178.2±31.80114.3±34.83123.5±34.3945.5±8.9345.7±10.06110.7±46.88115.9±56.110.34±0.680.38±0.43Ezetimibe/simvastatin2.37±0.46Rosuvastatin2.23±0.41Ripa et al., 2021 [58]a randomized, double-blind, placebo-controlled, parallel-group trialSubjects with DM type 226 weeks5151LiraglutidePlacebo 65.9 (8.6)66.9 (7.8)454130.5 (5.3)29.3 (3.8)(mmol/L)4.1 (0.8)4.1 (0.8)(mmol/L)2.1 (0.7)2.1 (0.6)(mmol/L)1.2 (0.4)1.3 (0.3)(mmol/L)2.1 (1.2)1.6 (0.8)(mmol/L)1.6 [0.99 to 3.9]1.5 [0.75 to 2.9]Active segments2.1 (0.30)2.0 (0.29)Most diseased segments2.7 (0.72)2.4 (0.63)Whole vessels1.9 (0.33)2.0 (0.37)Singh et al., 2016 [35]Prospective multicenter study (clinical trial), USSubjects with atherosclerosis3 months1540Atorvastatin61±941 (76)31.3±4.532.9±11.4ND97.7±25.4103.4±24.746.07±12.546.36±15.9NDNDWithout HRM1.67±0.32HRM1.95±0.43Stiekema et al., 2018 [43]Multicenter, randomized, double blind, placebo-controlled trialSubjects with clinically evident atherosclerotic cardiovascular disease16 weeks6564Evolocumab 420 mg,Placebo 59 (55-65)60.5(54.0-68.0)26(40)34 (53.1)26.7(24.2-29.0)26.6(24.0-28.9)228.3±50.2224.3±42.5146.9±42.5143.1±34.854.1±15.458.0±15.554.1±19.358.0±38.71.1 (0.6-2.2)1.0(0.6-1.6)MDS TBR, index vessel2.2(2.0-2.5)2.2(1.9-2.6)Tahara et al., 2006 [6]Prospective randomized controlled study, JapanThe subjects underwent voluntary cancer screening3 months2122Simvastatin 5 or 10 mg/day.Dietary management62±665±913 (61.9)14 (63.6)22.8±223.6±3.3NDND140±27132±2755±1051±16141±68156±940.09±0.110.11±0.161.69±0.27Tawakol et al., 2013 [21]This double-blind, randomized, active-comparator study, USSubjects with arterial inflammation3 months3434Atorvastatin 10 mg/dayAtorvastatin80 mg/day61 (53-68)58.5 (53-68)26 (76)26 (76)31.3 (26.9-32.5)32 (26.7-35.5)176.5 (161-192)178(154-203)104 (86-118)107.5(85-129)49 (43-60)44 (39-48)114.5 (78-182)129 (87-197)NDMDS2.34 (2.012.93)2.48 (2.23-2.81)WV2.21(2.02-2.49)2.28 (2.06-2.52)Watanabe et al., 2015 [20]Prospective randomized comparative study, JapanSubjects with hyperlipidemia6 months1010Pitavastatin 2 mg/day, Pravastatin 10 mg/day.68±564±117 (70)8 (80)NDND202±67225±21150±21142±2452±1254±15134±35167±632.8±4.11.7±2.21.29±0.221.19±0.16Wu et al., 2012 [19]Prospective, open-label, TaiwanSubjects with atherosclerosis3 months43Atorvastatin 40 mg/day54±1024 (71)24.5± 3.2199±42108±3645±12154±701.2±1.41.31±0.21 Characteristics of the Included Studies 20 10 Adalimumab 40 mg/day, placebo 56.05±10.95 57.40±7.60 17 (85) 6 (60) ND ND 177.88±37.51 180.97±44.08 105.95±37.51 109.82±33.26 41.76±12.37 40.60±8.12 65.35±30.94 90.10±66.51 4.22±3.66 4.28±2.65 Ascending aorta 1.86±0.35 2.04±0.51 Carotid arteries 1.65±0.25 1.84±0.29 17 18 50.5±6.5 52.3±7.9 12 (71) 18 (100%) 27.0±4.0 24.4±3.2 45.2±0.74 48.8±0.69 Thoracia aorta 2.99 ±.45 2.99 ±.32 21 19 DPP-4 inhibitor linagliptin 5mg/day placebo Linagliptin 2.12 [1.99-2.26] Placebo 2.09 [1.96-2.21] 34 33 32 losmapimod 7.5 mg twice daily, losmapimod 7.5 mg once daily, placebo 62.3±5.90 65.3±5.94 63.7±6.37 29 28 28 29.8±3.68 28.0±3.35 28.9±3.44 143.24 (28.65) 144.24 (28.76) 150.97 (49.64) 74.32 (23.63) 77.61 (19.85) 85.71 (25.79) 44.79 (11.97) 47.49 (12.39) 47.49 (10.66) 123.89 (45.04) 129.20 (65.66) 144.25 (49.65) 1.30 (114) 1.30 (146) 1.00 (133) Index vessel HD 2.07±0.31 LD 2.05±0.22 Placebo 1.94±0.24 24 24 24 63.1±5.9 62.8±7.1 16 (66.7) 18 (75.0) ND ND ND ND 92±19 91±24 53±14 49±11 ND ND 1.0(2.4) 1.6(3.4) 2.41±0.33 2.50±0.96 64 66 62.6 (8.2) 64.6 (7.8) 51 (80) 55 (83) 29.6 (4.8) 29.8 (6.2) 143.08 (27.06) 146.95 (27.06) 73.47 (23.20) 73.47 (19.33) 42.54 (11.60) 46.40 (15.47) 54.14 (38.67-73.47) 58.00 (38.67-69.61) 1.4 (0.6-3.7) 1.4 (0.8-2.8) MDS 2.7 (0.7) 2.8 (0.7) Mean 1.8 (0.4) 1.9 (0.3) 24 21 56.6 (9.67) 59.1 (7.20) 23 (95.8) 19 (90.5) 29.6 (5.14) 28.3 (3.90) 154.0 (51.90) 158.6 (47.94) 83.5 (41.61) 92.2 (36.56) 41.6 (9.07) 39.3 (8.90) 137.0(110.46) 135.2(64.39) Mean of mean 1.60±0.26 1.62±0.30 MDS 2.25±0.28 2.25±0.43 46 45 47.9 (12.7) 47.0 (14.7) 33 (71.1) 28 (62.2) 31.09 (6.8) 32.75 (7.8) 15 15 55±10 53±11 8 (53.5) 7 (46.7) ND ND 234±36 244±25 150±28 162±20 48±14 47±13 170±121 189±81 1.0±0.6 1.4±0,9 Ascending aorta 1.11±0.10 1.15±0.14 Femoral artery 1.10±0.16 1.12±0.11 10 5 115.00±40.00 109.60±32.08 64.69±31.16 63.8±26.09 34.40±6.97 32.20±4.43 117.00±72.56 122.80±93.84 9.15 ± 3.84 8.14 ± 4.71 Right carotid 0.92 ± 0.27 0.81 ± 0.19 Left carotid 0.78 ± 0.20 0.82 ± 0.15 Aorta 1.20 ± 0.27 1.35 ± 0.26 Lo et al. 2015 [39] 19 21 Atorvastatin 40 mg/day, placebo 52.2±3.7 50.0±5.6 15(79) 17(81) 25.6±2.9 25.8±4.8 198.8±37.9 192.2±27.1 123.7±36.7 124.9±32.1 51.8±19.3 50.7±15.1 120.5 (97.4-204.6) 113.4 (92.1-135.5) 0.8 (0.3-1.9) 1.1 (0.4-2.4) Aorta 2.08±0.32 2.20±0.37 Segment of aorta 2.18±0.33 2.26±0.37 RA 2.02±0.22 CVD 1.74±0.22 31 21 Pioglitazone 15-30 mg/day Glimepiride 0.5-4 mg/day 68.2±7.3 68.0±9.1 22 17 24.9±3.3 24.8±3.6 ND ND 111±26 119±24 50±12 51±13 105 (85-131) 121 (81-165) 0.78 (0.37-2.07) 0.72(0.41-1.51) Pioglitazone 1.46±0.29 Glimepiride 1.35±0.26 Nitta et al. 2013 [59] 25 22 Pioglitazone 15-30 mg/day Glimepiride 0.5-4 mg/day 68.8±7.2 67.3±9.3 19 18 ND ND ND ND 108.4±23.8 117.6±24.8 49.9±12.8 51.3±13.0 105.0 (79.5-125.5) 120.0 (119.5-145.5) 0,78 (0.34-1.93) 120.0(74.8-164.0) Pioglitazone 1.39±0.32 Glimepiride 1.45±0.29 25 25 62.5±7.4 59.2±8.8 22 21 ND ND 174.2±38.90 178.2±31.80 114.3±34.83 123.5±34.39 45.5±8.93 45.7±10.06 110.7±46.88 115.9±56.11 0.34±0.68 0.38±0.43 Ezetimibe/simvastatin 2.37±0.46 Rosuvastatin 2.23±0.41 51 51 Liraglutide Placebo 65.9 (8.6) 66.9 (7.8) 45 41 30.5 (5.3) 29.3 (3.8) (mmol/L) 4.1 (0.8) 4.1 (0.8) (mmol/L) 2.1 (0.7) 2.1 (0.6) (mmol/L) 1.2 (0.4) 1.3 (0.3) (mmol/L) 2.1 (1.2) 1.6 (0.8) (mmol/L) 1.6 [0.99 to 3.9] 1.5 [0.75 to 2.9] Active segments 2.1 (0.30) 2.0 (0.29) Most diseased segments 2.7 (0.72) 2.4 (0.63) Whole vessels 1.9 (0.33) 2.0 (0.37) 15 40 31.3±4.5 32.9±11.4 97.7±25.4 103.4±24.7 46.07±12.5 46.36±15.9 Without HRM 1.67±0.32 HRM 1.95±0.43 65 64 Evolocumab 420 mg, Placebo 59 (55-65) 60.5(54.0-68.0) 26(40) 34 (53.1) 26.7(24.2-29.0) 26.6(24.0-28.9) 228.3±50.2 224.3±42.5 146.9±42.5 143.1±34.8 54.1±15.4 58.0±15.5 54.1±19.3 58.0±38.7 1.1 (0.6-2.2) 1.0(0.6-1.6) MDS TBR, index vessel 2.2(2.0-2.5) 2.2(1.9-2.6) 21 22 Simvastatin 5 or 10 mg/day. Dietary management 62±6 65±9 13 (61.9) 14 (63.6) 22.8±2 23.6±3.3 ND ND 140±27 132±27 55±10 51±16 141±68 156±94 0.09±0.11 0.11±0.16 34 34 Atorvastatin 10 mg/day Atorvastatin 80 mg/day 61 (53-68) 58.5 (53-68) 26 (76) 26 (76) 31.3 (26.9-32.5) 32 (26.7-35.5) 176.5 (161-192) 178(154-203) 104 (86-118) 107.5(85-129) 49 (43-60) 44 (39-48) 114.5 (78-182) 129 (87-197) MDS 2.34 (2.012.93) 2.48 (2.23-2.81) WV 2.21(2.02-2.49) 2.28 (2.06-2.52) 10 10 68±5 64±11 7 (70) 8 (80) ND ND 202±67 225±21 150±21 142±24 52±12 54±15 134±35 167±63 2.8±4.1 1.7±2.2 1.29±0.22 1.19±0.16 The origins of the studies were the United States of America, Canada, Japan, United Kingdom, South Korea, Iran, Denmark, the Netherlands and Taiwan. Four out of 22 studies were multicenter and 18 studies were single-center. Inclusion criteria varied considerably. In general, patients aged 18–75 years and indicated with CVD or having risk factors on developing CVD were included. The main exclusion criteria were participants diagnosed with newly onset infections or chronic infections. Quantification of arterial [18F]FDG uptake Quantification of vascular [18F]FDG uptake is essential for evaluating inflammatory activity and monitoring therapeutic effects in atherosclerosis imaging studies. Several quantitative parameters have been used throughout the literature, each with specific advantages and limitations. The most straightforward parameter is the SUV, which reflects tracer uptake normalized for injected activity and body weight. SUV measurements are relatively easy to obtain and widely available. However, arterial SUV measurements may be influenced by several factors, including blood-pool activity, circulation time, body composition, serum glucose levels, and technical imaging parameters. To overcome some of these limitations, most vascular PET studies use the TBR, in which arterial SUV is corrected for venous blood-pool activity. TBR is generally considered more reproducible and better reflects true arterial wall inflammation compared to SUV alone. Consequently, TBR has become the most frequently applied quantitative parameter in vascular inflammation imaging studies. Several studies additionally evaluate the most diseased segment (MDS)-TBR, which focuses specifically on arterial regions with the highest inflammatory activity. This approach may improve sensitivity for detecting treatment-induced changes in highly inflamed plaques. However, MDS-based analyses may also increase susceptibility to image noise and partial volume effects. Despite the widespread use of these quantitative measures, important methodological limitations remain. Arterial PET imaging is affected by the limited spatial resolution of current PET systems, partial volume effects, motion artifacts, and variability in acquisition protocols, including fasting duration, uptake time, and blood glucose levels. These factors complicate direct comparison between studies and emphasize the need for further standardization of vascular PET imaging protocols. Risk of bias within studies Risk of bias is being evaluated according to the Risk of Bias tool-2 for RCTs provided by Cochrane [27]. In Table 5 of appendix D, the results of the assessment of the randomized controlled studies are shown. In Table 6, the results of the open-label non-randomized studies are shown, using the ROBINS-I bias tool. No differences in total bias between the individual studies can be established. However, pharmaceutical companies are funding multiple studies. That fact alone is considered a form of high bias. Table 5The bias of each individual randomized controlled trialStudyBias arising from the randomization processBias due to deviations from intended interventionsBias due to missing outcome dataBias in measurement of the outcomeBias in selection of the reported resultBissonnette et al. 2012 [54]LLLLLBoczar et al., 2021 [40]LLLLLDe Boer et al., 2017 [57]LLSCSCLElkhawad et al., 2012 [25]LLSCLLEmami et al., 2015 [24]LLSCSCLFayad et al., 2011 [23]LLLLLGaztanaga et al., 2015 [49]LLLLLGelfand et al., 2020 [55]LLLLLIshii et al., 2010 [41]LHLLLJamialahmadi et al., 2022 [50]LLLLLLo et al.2015 [39]LLLLLMizoguchi et al. 2011 [60]LLLLLStiekema et al., 2018 [43]LLLLLNitta et al.2013 [59]LLLLLOh et al., 2019 [42]LHLLLRipa et al., 2021 [58]LLLLLSingh et al., 2016 [35]LLLLLTahara et al., 2006 [6]LHLLLTawakol et al., 2013 [21]LLLLLWatanabe et al., 2015 [20]LLLLLL, low risk of bias; H, high risk of bias; SC, Some Concerns The bias of each individual randomized controlled trial Lo et al. 2015 [39] Nitta et al. 2013 [59] L, low risk of bias; H, high risk of bias; SC, Some Concerns Table 6Risk analysis in non-randomized controlled studiesStudy Bias due to Confounding Bias in selection of participants into the study Bias in classification of intervention Bias due to deviation from intended intervention Bias due to missing data Bias in measurement of outcomes Bias in selection of the reported result Overall Assessment of bias Risk of bias pre-intervention and at intervention domains Risk of bias post-intervention domains Mäki-Petäjä et al., 2012 [53]ModerateSeriousLowSeriousLowLowLowSeriousWu et al., 2012 [19]ModerateSeriousLowModerateLowLowLowSeriousLow, low risk of bias; Serious, high risk of bias; Moderate, moderate risk of bias Risk analysis in non-randomized controlled studies Low, low risk of bias; Serious, high risk of bias; Moderate, moderate risk of bias Results of individual studies Appendix E provides a detailed description regarding the used articles and their outcomes. Figures 2 and 3 shows the results of the twentytwo included studies (Table 7). Visual presentation of the results from the included studies Changes in vascular inflammation assessed by [18F]FDG PET after lipid-lowering and anti-inflammatory therapies Table 7Characteristics of the included studiesAuthorOutcome measureOutcomeTotal CholesterolLDL CholesterolHDL CholesterolTriglyceridesC-Reactive proteinTBR index vessel (baseline-measurement)mean ± SDΔ TBR index vessel(intervention) group vs. controlBissonnette et al. 2012 [54]The primary end point was the change in the average of maximum TBR values (MeanMAX TBR) of carotid arteries and ascending aorta from baseline to week 15, analyzed in the vessel with highest baseline TBRThe study did not meet its primary outcomeNSNSNSNS51% decreasep = 0.002Adalimumab–0.23 [95% CI, − 0.39 to − 0.08]; P = 0.004Placebo(–0.10 [95% CI, − 0.32 to 0.12]; P = 0.35)–0.13 [95% CI, − 0.01 to 0.14]; (P = 0.32)Boczar et al., 2021 [40]The change in TBR values after intervention, these were compared to baseline measuresSignificant reduction of FDG uptake in the thoracic aortaNDNDNDNDNDThoracic aorta:Statin-treated− 11.88 ± 18.18%Thoracic aorta:Statin-treated− 19.1 ± 24.2%Control4.3 ± 15.4%, p = 0.003).De Boer et al., 2017 [57]The change in TBR values after intervention, these were compared to baseline measuresThis is the first randomized placebo-controlled trial that demonstrates that 26 weeks of treatment with linagliptin decreases arterial FDG uptake in subjects with early type 2 diabetesNSNSNS-0.49p = 0.019NSLinagliptin2.12 [1.99–2.26] -1.99 [1.90–2.11]Placebo2.09 [1.96–2.21]-2.15 [2.01–2.28]0.18 [95% CI, 0.04–0.32] (p = 0.015)Elkhawad et al., 2012 [25]The primary endpoint, change from baseline in average TBR across all segments in the index vessel compared to the placebo groupThe result were non-significant changes for the primary endpoint of average vessel TBR after interventionNDNDNDNDHD vs. control% reduction: -28% [95% CI: -46, -5]p = 0.023HD losmapimod2.07 0.31–1.93 0.3p = 0.003LD losmapimod2.05 0.22–1.93 0.20p < 0.001Control1.94 0.24–1.89 0.25p = 0.005HD losmapimod vs. control∆TBR: -0.04 CI: [-0.14 to -0.06], p = 0.452LD losmapimod vs. control∆TBR: -0.02 [95% CI: [-0.11 to -0.06], p = 0.579Emami et al., 2015 [24]The change in TBR of the atorvastatin group as well as the BMS-582949 were compared to a placebo groupTreatment with BMS-582949 did not reduce arterial inflammation relative to placeboNDPlacebo6.96 (-6.78-20.69) N/AAtorvastatin-16.22 (-25.91,-6.53)p = 0.006BMS-5829494.59 (-10.05-19.23) p0.808Placebo3.82 (-3.85-11.49) N/AAtorvastatin-3.26 (-8.12-1.59) p = 0.113BMS-5829490.98 (-6.44-8.4) p = 0.586NDPlacebo16.71 [133.45] N/A Atorvastatin-17.44 [54.68] p = 0.043BMS-58294933.83 [153.91] p = 0.617Placebo-0.07 (-0.23-0.09)Atorvastatin-0.09 (-0.25-0.06)BMS-5829490.02 (-0.14-0.18)BMS-582949 vs. control0.10 [95% CI: -0.11, 0.30], p = 0.34Fayad et al., 2011 [23]The primary endpoint was absolute or percent change, or both, from baseline in arterial wall 18F-FDG uptake (assessed as TBR) within the index vessel.Dalcetrapib showed no evidence of a pathological effect related to the arterial wall over 24 months.NDPlacebo7.3%Dalcetrapib0.1%Placebo4.0%Dalcetrapib30.9%Placebo3.8%Dalcetrapib 7·0%Placebo0·0%Dalcetrapib33·3%Placebo-0.26(0.08)Dalcetrapib-0.19(0.08)0.07 (-0.11-0.25)p = 0.51Gaztanaga et al., 2015 [49]The primary outcome was the effect of 100 mg, VIA-2291 relative to placebo on mean of max TBR of the whole index vessel after 24 weeks of daily treatmentInhibition of 5-LO with VIA-2291 is not associated with significant reductions in vascular inflammation quantified by FDG-PET. As well no significance seen in blood inflammatory markersNDNDNDNDVIA-22910.06 (-0.18-0.30)Placebo-0.18 (-0.44-0.08)VIA-22912.07 ± 0.22Placebo2.01 ± 0.25P = 0.34Gelfand et al., 2020 [55]The primary outcome was to evaluate the effect of secukinumab 300 mg compared to placebo with respect to the change in TBR from baseline at Week 12.Secukinumab exhibited a neutral impact on aortic vascular inflammation after treatment with secukinumabSecukinumab1.1 p = 0.7380Secukinumab1.4 p = 0.6567Secukinumab−0.6 p = 0.5219Secukinumab5.9 p = 0.4121Secukinumab−1.6 p = 0.0664Secukinumab2.6% (95% CI, − 2.5%, 7.6%); P = 0.31Placebo3.3% (95% CI, − 0.8%, 7.5%); P = 0.12−0.053 (95% CI: −0.169, 0.064; P = 0.37)Ishii et al., 2010 [41]After 6 months the change in TBR values was compared to baseline measures in the aorta and femoral arterySix months of treatment with atorvas- tatin 20 mg, but not 5 mg, was associated with a significant reduction in TBR in the ascending aorta and femoral arteryAtorvastatin 5 mg-19.1%p = 0.001Atorvastatin 20 mg25.6%p < 0.001Atorvastatin 5 mg-32.3%p < 0.001Atorvastatin 20 mg-38.55%p < 0.001Atorvastatin 5 mg3.1%p = 0.71Atorvastatin 20 mg13.5%p = 0.047Atorvastatin 5 mg-12.4%p = 0.35Atorvastatin 20 mg-26.5%p = 0.026Atorvastatin 5 mg-44.9p < 0.001Atorvastatin 20 mg-49.3p < 0.001Atorvastatin 5 mg-0.04 (0.10)p = 0.19Atorvastatin 20 mg-0.10 (0.12)p = 0.007Overall reductionP = 0.003Jamialahmadi et al., 2022 [50]the potential effect of intravenous trehalose in reducing arterial wall inflammation in patients with established ASCVD and increased systemic markers of inflammatory activity.no significant reduction in arterial wall inflammation could be observedTrehalose129.50 ± 45.78Δ + 14.50 ± 40.16Placebo107.20 ± 17.54Δ -2.40 ± 19.55Trehalose80.50 ± 36.53Δ + 15.90 ± 25.77Placebo60.00 ± 13.39Δ + 3.80 ± 16.3Trehalose35.70 ± 8.90Δ + 1.30 ± 5.20Placebo34.00 ± 4.35Δ + 1.80 ± 3.49Trehalose161.20 ± 91.81Δ + 44.20 ± 75.74Placebo136.20 ± 104.94Δ + 13.40 ± 26.19Trehalose11.26 ± 6.82Δ + 2.10 ± 6.89Placebo12.40 ± 5.01Δ + 4.26 ± 6.78Right carotidΔ -0.015 ± 0.36p = 0.894Δ + 0.036 ± 0.17p = 0.677Left carotidΔ + 0.122 ± 0.24p = 0.146Δ + 0.012 ± 0.11p = 0.825AortaΔ + 0.11 ± 0.33p = 0.310Δ -0.01 ± 0.30p = 0.945Right carotidp = 0.765Left carotidp = 0.360AortaP = 0.501Lo et al.2015 [39]The pre-specified primary endpoint was arterial inflammation, as assessed by FDG-PET of the aorta.Significant effects of statin therapy on arterial inflammation of the aorta by FDG-PET were not seen.Atorvastatin-1.23 [-1.53,-0.93]Control0.12 [-0.12-0.37]p < 0.0001Atorvastatin−1·00[95% CI − 1·38 − 0·61]Control0·30[0·04 − 0·55] mmol/L, p < 0·0001Atorvastatin0.02 [-0.11-0.16]Control-0.04 [-0.17-0.09]p = 0.48Atorvatstin-0.10 (-0.46-0.44)Control0.08(-0.46-0.38)p = 0.64Atorvastatin-0.3 [-0.6-0.0)Control0.1[-0.2-0.4]AtorvastatinΔ − 0·03 [95% CI: −0·17, 0·12]ControlΔ − 0·06 [− 0·25, 0·13], p = 0·77p = 0.77Mäki-Petäjä et al., 2012 [53]The change in TBRs in the aorta and MDS after 8 weeks of intervention compared to a placebo group.Anti-tumor necrosis factor-alpha therapy reduces aortic inflammation in patients with rheumatoid arthirtisNDNDNDND11.0(4.0–29.0)-3.0 (2.0–10.0)p = 0.0072.02 ± 0.22–1.90 ± 0.29P = 0.03P = 0.0001Mizoguchi et al. 2011 [60]Effects of treatment on atherosclerotic plaque inflammation were evaluated by FDG-PETPioglitazone could attenuate atherosclerotic plaque inflammation in patients with impaired glucose tolerance or in diabetic patients independent of glucose lowering effect.NDPioglitazone49.7 ± 12.4–55.3 ± 13.8 p < 0.01Glimepiride51.0 ± 13.2–53.1 ± 12.7NSPioglitazone11 ± 26–109 ± 27NSGlimepiride119 ± 24–118 ± 20NSPioglitazone105 (85–131) -120 (82–151)NSGlimepiride121 (81–165) − 123 (90–209)NsPioglitazone0.78 (0.37–2.07) – 0.51 (0.261.02)p < 0.01Glimepiride0.72 (0.41–1.51) – 1.04 (0.5–2.10)p < 0.05Pioglitazone1.46 ± 0.29–1.32 ± 0.22, p < 0.01Glimepiride1.35 ± 0.26–1.41 ± 0.30, p = NSp < 0.01Nitta et al.2013 [59]Effects of the treatments on vascular inflammation of the left main trunk were evaluated by FDG-PET/CT angiography at baseline and end of the study.Pioglitazone attenuated left main trunk inflammation in patients with impaired glucose tolerance or DM in a glucose-lowering independent mannerNDPioglitazone108.4 ± 23.8 106.4 ± 27.7 p = 0.714Glimepiride117.6 ± 24.8 118.1 ± 19.8p = 0.903Pioglitazone49.9 ± 12.8–54.6 ± 14.9p = 0.017Glimepiride51.3 ± 13.0–53.3 ± 12.5p = 0.161Pioglitazone105.0 (79.5–125.5) 120.0 (80.5–148.5) p = 0.431Glimepiride120.0 (74.8–164.0) 119.5 (85.0–207.8) p = 0.153Pioglitazone0.78 (0.34–1.93) 0.53 (0.27–1.15) p = 0.228Glimepiride0.61 (0.35–1.47) 0.93 (0.45–2.00) p = 0.018Pioglitazone1.39 ± 0.32–1.26 ± 0.29p = 0.033Glimepiride1.45 ± 0.29–1.54 ± 0.35p = 0.261–0.12 ± 0.06 vs. 0.09 ± 0.07p = 0.032Oh et al., 2019 [42]The changes in TBR values of the index vessel after 6 months compared to baseline TBR values.The outcome of treatment with ezetimibe/simvastatin versus rosuvastatin resulted in a similar improvement in the inflammation of the carotid atherosclerotic plaque.135.6 ± 23.65p < 0.001129.4 ± 23.37p < 0.00187.3 ± 20.00p < 0.00181.1 ± 21.9p < 0.00145.2 ± 7.95NS46.7 ± 8.32NS113.8 ± 43.70NS115.2 ± 44.93NS0.10 ± 0.17p = 0.0900.11 ± 0.24p = 0.016Ezetimibe/simvastatin2.37 ± 0.46–2.07 ± 0.29p = 0.002Rosuvastatin2.23 ± 0.41–2.09 ± 0.46p = 0.077Ezetimibe/simvastatin-10.22% ±17.49Rosuvastatin-5.84% ±15.78p = 0.357Ripa et al., 2021 [58]26 weeks treatment with liraglutide would reduce vascular inflammation assessed as [18 F]FDG uptake compared with placebo.liraglutide did not change vascular inflammation assessed as [18 F]-fluorodeoxyglucose uptake compared with placeboND0.1 (− 0.2 to 0.3)p = 0.13−0.1 (− 0.3 to 0.1)p = 0.99NDND−0.11 [− 0.91 to 0.27]p = 0.130.03 [− 0.22 to 0.42]p = 0.99Active segments−0.04 (− 0.17 to 0.08)p = 0.50−0.09 (− 0.19 to 0.01)p = 0.07Most diseased segments−0.22 (− 0.40 to − 0.03)p = 0.02−0.24 (− 0.44 to − 0.04)p = 0.02Whole vessels0.07 (− 0.05 to 0.18)p = 0.270.01 (− 0.10 to 0.11)p = 0.88Active segmentsp = 0.53Most diseased segmentsp = 0.87Whole vesselsp = 0.46Singh et al., 2016 [35]Baseline 18F-FDG uptakes in the mentioned areas were compared to uptake after 12 weeks of treatment with atorvastatin.There was observed that the anti-inflammatory impact of statins is substantially greater within coronary plaques that contain HRM features.NDNDNDNDNSLMCA with HRM−0.18 [− 0.35 to − 0.004]LMCA without HRM0.09 [− 0.06 to 0.26];P = 0.02Stiekema et al., 2018 [43]Percentage change from baseline in MDS TBR of the index vessel after 16 weeks interventionAfter 16 weeks of treatment evolocumab did not lead to a reduction in atrial wall inflammation.Treatment difference:-38.8%(-42.5 to -35.1)p < 0.001Treatment difference:-60.7%(-65.8 to -55.5)p < 0.001Treatment difference:9.3 (4.1–14.5)p < 0.001Treatment difference:-16.4 (-25.3 to -7.5)p < 0.001Evolovumab-1.2 (7.9) mg/LPlacebo-0.4 (4.5) mg/LEvolovumab-8.3% (-11.6% to -5.0%)Placebo-5.31 (-8.6% to -2.0%)Treatment difference-3.00 (7.40–1.39)(p = 0.18)Tahara et al., 2006 [6]In individual plaques, the changes in the SUV (ΔSUV) were calculated by subtracting the SUV at baseline from the SUV after 3-month treatment. The subject wise SUV and ΔSUV were calculated by averaging the plaque wise SUVs and ΔSUVs, respectively in each subject.Simvastatin over a 12-week period resulted in a significant reduction of arterial inflammationNDSimvastatin132 ± 27–93 ± 16*Diet140 ± 27–142 ± 30Simvastatin51 ± 94–134 ± 75Diet55 ± 10–57 ± 11Simvastatin156 ± 94–134 ± 75Diet141 ± 68–132 ± 67Simvastatin0.11 ± 16-0.07 ± 0.06Diet0.09 ± 0.11 − 0.06 ± 0.07SimvastatinP < 0.01DietNSSimvastatin vs. DietP < 0.01Tawakol et al., 2013 [21]FDG-PET/CT imaging of the ascending thoracic aorta and carotid arteries was performed at baseline, 4 and 12 weeks after randomization. Primary endpoint analysis: evaluating change from baseline in the TBR within the MDS of the index vessel after 4 and 12 weeksStatin therapy produced significant rapid dose-dependent reductions in FDG uptake that may represent changes in atherosclerotic plaque inflammation.Atorvastatin 10 mgNDAtorvastatin 80 mgNDAtorvastatin 10 mgNDAtorvastatin 80 mgNDAtorvastatin 10 mgNDAtorvastatin 80 mgNDAtorvastatin 10 mgNDAtorvastatin 80 mgNDAtorvastatin 10 mgNDAtorvastatin 80 mgNDAtorvastatin 10 mg-4.2% [–2.3%-10.4%]p > 0.1Atorvastatin 80 mg-14.42% [8.7%-19.8%]p < 0.001% Red From 10 mg atorvastatin10.6 (2.2–18.3)p = 0.01Watanabe et al., 2015 [20]After six months of treatment, the same regions as at baseline were selected by referring CT images. Target background ratios were used to measure max SUV of plaques and to evaluate percent change of TBR before and after treatment.The pravastatin treatment was less effective on plaque inflammation than pitavastatin treatment. This trend was the same in the carotid arteries and the thoracic aorta.Pitavastatin202 ± 67–154 ± 22*Pravastatin225 ± 21–185 ± 16*Pitavastatin150 ± 21–80 ± 16*Pravastatin142 ± 24–103 ± 18*Pitavastatin52 ± 12–52 ± 11Pravastatin54 ± 15–55 ± 13Pitavastatin134 ± 35–107 ± 52Pravastatin167 ± 63–135 ± 71Pitavastatin2,883 ± 4,176-3,581 ± 8,445Pravastatin1,747 ± 2,239-3,928 ± 5,025Pitavastatin1.29 ± 0.22 to 1.04 ± 0.23*Pravastatin1.19 ± 0.16 to 1.19 ± 0.18)NDWu et al., 2012 [19]Arterial FDG activity (in maximum and mean TBR) was compared before and after therapy and compared to a historical control group (without cardiovascular disease, malignancy, renal or hepatic disease).The medium dose of atorvastatin over a 12-week period resulted in a significant reduction of arterial inflamma- tion as well as various circulating biomarkers.149 ± 38 (95–290)p < 0.000180 ± 27 (37–153)p < 0.000140 ± 8 (26–59)p = 0.045117 ± 88 (47–622)p = 0.00162.7 ± 3.6 (0.1–13.8)p = 0.01731.83 ± 0.37 (1.42–3.21) -1.48 ± 0.23 (1.35–2.07)NDValues are expressed as mean ± SD. * Mean (interquartile range). Abbreviations: ND, no data; BMI, body mass index; MDS, most-diseased segment; WV, whole vessel Characteristics of the included studies 51% decrease p = 0.002 Adalimumab –0.23 [95% CI, − 0.39 to − 0.08]; P = 0.004 Placebo (–0.10 [95% CI, − 0.32 to 0.12]; P = 0.35) Thoracic aorta: Statin-treated − 11.88 ± 18.18% Thoracic aorta: Statin-treated − 19.1 ± 24.2% Control 4.3 ± 15.4%, p = 0.003). -0.49 p = 0.019 Linagliptin 2.12 [1.99–2.26] -1.99 [1.90–2.11] Placebo 2.09 [1.96–2.21]-2.15 [2.01–2.28] HD vs. control % reduction: -28% [95% CI: -46, -5] p = 0.023 HD losmapimod 2.07 0.31–1.93 0.3 p = 0.003 LD losmapimod 2.05 0.22–1.93 0.20 p < 0.001 Control 1.94 0.24–1.89 0.25 p = 0.005 HD losmapimod vs. control ∆TBR: -0.04 CI: [-0.14 to -0.06], p = 0.452 LD losmapimod vs. control ∆TBR: -0.02 [95% CI: [-0.11 to -0.06], p = 0.579 Placebo 6.96 (-6.78-20.69) N/A Atorvastatin -16.22 (-25.91,-6.53) p = 0.006 BMS-582949 4.59 (-10.05-19.23) p0.808 Placebo 3.82 (-3.85-11.49) N/A Atorvastatin -3.26 (-8.12-1.59) p = 0.113 BMS-582949 0.98 (-6.44-8.4) p = 0.586 Placebo 16.71 [133.45] N/A Atorvastatin -17.44 [54.68] p = 0.043 BMS-582949 33.83 [153.91] p = 0.617 Placebo -0.07 (-0.23-0.09) Atorvastatin -0.09 (-0.25-0.06) BMS-582949 0.02 (-0.14-0.18) BMS-582949 vs. control 0.10 [95% CI: -0.11, 0.30], p = 0.34 Placebo 7.3% Dalcetrapib 0.1% Placebo 4.0% Dalcetrapib 30.9% Placebo 3.8% Dalcetrapib 7·0% Placebo 0·0% Dalcetrapib 33·3% Placebo -0.26(0.08) Dalcetrapib -0.19(0.08) 0.07 (-0.11-0.25) p = 0.51 VIA-2291 0.06 (-0.18-0.30) Placebo -0.18 (-0.44-0.08) VIA-2291 2.07 ± 0.22 Placebo 2.01 ± 0.25 Secukinumab 1.1 p = 0.7380 Secukinumab 1.4 p = 0.6567 Secukinumab −0.6 p = 0.5219 Secukinumab 5.9 p = 0.4121 Secukinumab −1.6 p = 0.0664 Secukinumab 2.6% (95% CI, − 2.5%, 7.6%); P = 0.31 Placebo 3.3% (95% CI, − 0.8%, 7.5%); P = 0.12 Atorvastatin 5 mg -19.1% p = 0.001 Atorvastatin 20 mg 25.6% p < 0.001 Atorvastatin 5 mg -32.3% p < 0.001 Atorvastatin 20 mg -38.55% p < 0.001 Atorvastatin 5 mg 3.1% p = 0.71 Atorvastatin 20 mg 13.5% p = 0.047 Atorvastatin 5 mg -12.4% p = 0.35 Atorvastatin 20 mg -26.5% p = 0.026 Atorvastatin 5 mg -44.9 p < 0.001 Atorvastatin 20 mg -49.3 p < 0.001 Atorvastatin 5 mg -0.04 (0.10) p = 0.19 Atorvastatin 20 mg -0.10 (0.12) p = 0.007 Overall reduction P = 0.003 Trehalose 129.50 ± 45.78 Δ + 14.50 ± 40.16 Placebo 107.20 ± 17.54 Δ -2.40 ± 19.55 Trehalose 80.50 ± 36.53 Δ + 15.90 ± 25.77 Placebo 60.00 ± 13.39 Δ + 3.80 ± 16.3 Trehalose 35.70 ± 8.90 Δ + 1.30 ± 5.20 Placebo 34.00 ± 4.35 Δ + 1.80 ± 3.49 Trehalose 161.20 ± 91.81 Δ + 44.20 ± 75.74 Placebo 136.20 ± 104.94 Δ + 13.40 ± 26.19 Trehalose 11.26 ± 6.82 Δ + 2.10 ± 6.89 Placebo 12.40 ± 5.01 Δ + 4.26 ± 6.78 Right carotid Δ -0.015 ± 0.36 p = 0.894 Δ + 0.036 ± 0.17 p = 0.677 Left carotid Δ + 0.122 ± 0.24 p = 0.146 Δ + 0.012 ± 0.11 p = 0.825 Aorta Δ + 0.11 ± 0.33 p = 0.310 Δ -0.01 ± 0.30 p = 0.945 Right carotid p = 0.765 Left carotid p = 0.360 Aorta P = 0.501 Lo et al. 2015 [39] Atorvastatin -1.23 [-1.53,-0.93] Control 0.12 [-0.12-0.37] p < 0.0001 Atorvastatin −1·00[95% CI − 1·38 − 0·61] Control 0·30[0·04 − 0·55] mmol/L, p < 0·0001 Atorvastatin 0.02 [-0.11-0.16] Control -0.04 [-0.17-0.09] p = 0.48 Atorvatstin -0.10 (-0.46-0.44) Control 0.08(-0.46-0.38) p = 0.64 Atorvastatin -0.3 [-0.6-0.0) Control 0.1[-0.2-0.4] Atorvastatin Δ − 0·03 [95% CI: −0·17, 0·12] Control Δ − 0·06 [− 0·25, 0·13], p = 0·77 11.0(4.0–29.0)-3.0 (2.0–10.0) p = 0.007 2.02 ± 0.22–1.90 ± 0.29 P = 0.03 Pioglitazone 49.7 ± 12.4–55.3 ± 13.8 p < 0.01 Glimepiride 51.0 ± 13.2–53.1 ± 12.7 NS Pioglitazone 11 ± 26–109 ± 27 NS Glimepiride 119 ± 24–118 ± 20 NS Pioglitazone 105 (85–131) -120 (82–151) NS Glimepiride 121 (81–165) − 123 (90–209) Ns Pioglitazone 0.78 (0.37–2.07) – 0.51 (0.261.02) p < 0.01 Glimepiride 0.72 (0.41–1.51) – 1.04 (0.5–2.10) p < 0.05 Pioglitazone 1.46 ± 0.29–1.32 ± 0.22, p < 0.01 Glimepiride 1.35 ± 0.26–1.41 ± 0.30, p = NS Nitta et al. 2013 [59] Pioglitazone 108.4 ± 23.8 106.4 ± 27.7 p = 0.714 Glimepiride 117.6 ± 24.8 118.1 ± 19.8 p = 0.903 Pioglitazone 49.9 ± 12.8–54.6 ± 14.9 p = 0.017 Glimepiride 51.3 ± 13.0–53.3 ± 12.5 p = 0.161 Pioglitazone 105.0 (79.5–125.5) 120.0 (80.5–148.5) p = 0.431 Glimepiride 120.0 (74.8–164.0) 119.5 (85.0–207.8) p = 0.153 Pioglitazone 0.78 (0.34–1.93) 0.53 (0.27–1.15) p = 0.228 Glimepiride 0.61 (0.35–1.47) 0.93 (0.45–2.00) p = 0.018 Pioglitazone 1.39 ± 0.32–1.26 ± 0.29 p = 0.033 Glimepiride 1.45 ± 0.29–1.54 ± 0.35 p = 0.261 –0.12 ± 0.06 vs. 0.09 ± 0.07 p = 0.032 135.6 ± 23.65 p < 0.001 129.4 ± 23.37 p < 0.001 87.3 ± 20.00 p < 0.001 81.1 ± 21.9 p < 0.001 45.2 ± 7.95 NS 46.7 ± 8.32 NS 113.8 ± 43.70 NS 115.2 ± 44.93 NS 0.10 ± 0.17 p = 0.090 0.11 ± 0.24 p = 0.016 Ezetimibe/simvastatin 2.37 ± 0.46–2.07 ± 0.29 p = 0.002 Rosuvastatin 2.23 ± 0.41–2.09 ± 0.46 p = 0.077 Ezetimibe/simvastatin -10.22% ±17.49 Rosuvastatin -5.84% ±15.78 p = 0.357 0.1 (− 0.2 to 0.3) p = 0.13 −0.1 (− 0.3 to 0.1) p = 0.99 −0.11 [− 0.91 to 0.27] p = 0.13 0.03 [− 0.22 to 0.42] p = 0.99 Active segments −0.04 (− 0.17 to 0.08) p = 0.50 −0.09 (− 0.19 to 0.01) p = 0.07 Most diseased segments −0.22 (− 0.40 to − 0.03) p = 0.02 −0.24 (− 0.44 to − 0.04) p = 0.02 Whole vessels 0.07 (− 0.05 to 0.18) p = 0.27 0.01 (− 0.10 to 0.11) p = 0.88 Active segments p = 0.53 Most diseased segments p = 0.87 Whole vessels p = 0.46 LMCA with HRM −0.18 [− 0.35 to − 0.004] LMCA without HRM 0.09 [− 0.06 to 0.26]; Treatment difference: -38.8%(-42.5 to -35.1) p < 0.001 Treatment difference: -60.7%(-65.8 to -55.5) p < 0.001 Treatment difference: 9.3 (4.1–14.5) p < 0.001 Treatment difference: -16.4 (-25.3 to -7.5) p < 0.001 Evolovumab -1.2 (7.9) mg/L Placebo -0.4 (4.5) mg/L Evolovumab -8.3% (-11.6% to -5.0%) Placebo -5.31 (-8.6% to -2.0%) Treatment difference -3.00 (7.40–1.39) (p = 0.18) Simvastatin 132 ± 27–93 ± 16* Diet 140 ± 27–142 ± 30 Simvastatin 51 ± 94–134 ± 75 Diet 55 ± 10–57 ± 11 Simvastatin 156 ± 94–134 ± 75 Diet 141 ± 68–132 ± 67 Simvastatin 0.11 ± 16-0.07 ± 0.06 Diet 0.09 ± 0.11 − 0.06 ± 0.07 Simvastatin P < 0.01 Diet NS Simvastatin vs. Diet P < 0.01 Atorvastatin 10 mg ND Atorvastatin 80 mg ND Atorvastatin 10 mg ND Atorvastatin 80 mg ND Atorvastatin 10 mg ND Atorvastatin 80 mg ND Atorvastatin 10 mg ND Atorvastatin 80 mg ND Atorvastatin 10 mg ND Atorvastatin 80 mg ND Atorvastatin 10 mg -4.2% [–2.3%-10.4%] p > 0.1 Atorvastatin 80 mg -14.42% [8.7%-19.8%] p < 0.001 % Red From 10 mg atorvastatin 10.6 (2.2–18.3) p = 0.01 Pitavastatin 202 ± 67–154 ± 22* Pravastatin 225 ± 21–185 ± 16* Pitavastatin 150 ± 21–80 ± 16* Pravastatin 142 ± 24–103 ± 18* Pitavastatin 52 ± 12–52 ± 11 Pravastatin 54 ± 15–55 ± 13 Pitavastatin 134 ± 35–107 ± 52 Pravastatin 167 ± 63–135 ± 71 Pitavastatin 2,883 ± 4,176-3,581 ± 8,445 Pravastatin 1,747 ± 2,239-3,928 ± 5,025 Pitavastatin 1.29 ± 0.22 to 1.04 ± 0.23* Pravastatin 1.19 ± 0.16 to 1.19 ± 0.18) 149 ± 38 (95–290) p < 0.0001 80 ± 27 (37–153) p < 0.0001 40 ± 8 (26–59) p = 0.045 117 ± 88 (47–622) p = 0.0016 2.7 ± 3.6 (0.1–13.8) p = 0.0173 Values are expressed as mean ± SD. * Mean (interquartile range). Abbreviations: ND, no data; BMI, body mass index; MDS, most-diseased segment; WV, whole vessel [18F]FDG PET in interventional studies with lipid lowering drugs Statins are the first-line treatment in lowering the total and LDL cholesterol levels [29]. This reduction is associated with a risk reduction on the onset and/or progression of coronary artery disease (CAD) [30]. Recent data propose that statins, in addition to their lipid-lowering capacity, can also reduce the production of reactive oxygen compounds and increase the resistance of LDL to oxidation [30, 31]. One of its properties is suggested to be the ability to limit the oxidation of LDL, contributing to their effectiveness in the prevention of atherosclerotic disorders [29]. In 2006, Tahara et al. investigated forty-three subjects who underwent a diagnostic [18F]FDG PET scan for cancer screening [6]. The conducted PET scan included images of the thoracic aorta and/or carotid arteries. Patients were randomized to either a statin group that received simvastatin (starting dose 5 or 10 mg/day) (n = 21) or a diet group that received diet management only (n = 22). Maximum SUVs were measured and after 3-months of treatment, simvastatin led to attenuated [18F]FDG uptakes in the arteries with significantly decreased SUVs (p < 0.01), a result not seen in the diet group. In 2012, a similar study was conducted in a different group of forty-three patients who never received statin treatment before but with diagnosed atherosclerosis. The subjects received atorvastatin (40 mg/day) for in total three months and underwent a baseline as well as a post-therapeutic follow-up [18F]FDG PET [19]. Arterial inflammation was measured in seven arterial territories including the ascending aorta, arch, thoracic descending aorta, abdominal aorta, and bilateral ilio-femoral arteries and was quantified as TBR. After three months, a significant decrease was observed in arterial inflammation as well as in various circulating biomarkers in the medium dose atorvastatin group [32]. Statins can be pharmacologically subdivided into hydrophilic and lipophilic agents [20, 33]. It might be possible that the strength of their pleiotropic effects can vary depending on the properties of a statin (respectively lipophilic or hydrophilic) [20]. Therefore, the goal of a 2015 published study was to examine the six-month effects of a strong lipophilic statin (pitavastatin) compared to a mild hydrophilic statin (pravastatin). Patients suffering from hyperlipidemia were randomly assigned into two treatment groups (n = 10 each): a pitavastatin and a pravastatin group. At baseline and after six months the [18F]FDG uptake in the thoracic aorta and carotid arteries were measured and quantified. It was observed that pitavastatin had a more favorable effect on inflammation reduction compared to pravastatin and that [18F]FDG PET was sensitive enough to detect the reduction in inflammation between the two different isoforms of statins [20]. More recently, a 12 weeks therapy with atorvastatin was evaluated whether it could reduce inflammation in the coronary arteries. Fifty-five subjects with or at high risk for atherosclerosis underwent [18F]FDG PET at baseline and after 12 weeks of treatment. To suppress physiological myocardial [18F]FDG uptake, subjects underwent dietary preparation prior to PET imaging. Coronary arterial inflammation was quantified as TBR in the left main coronary artery (LMCA). The presence of high-risk morphologies (HRM), defined as non-calcified or partially calcified plaques, in the LMCA was evaluated. In this study, TBRs above 1.6 were considered as high risk, which is an uniform cut-off value in comparable studies [34]. After 12 weeks the subjects with HRM were compared to patients without HRM in the coronaries. [18F]FDG PET was capable to demonstrate a significant reduction in inflammation within HRM patients [35]. However, the results of this study need to be interpreted cautiously. Scanning the coronaries is challenging or almost impossible by means of PET due to the small size of the coronaries (3–4 mm), which is in the limit of the spatial resolution of PET. In addition, the myocardium may show reasonably high physiological [18F]FDG uptake, impairing the differentiation between vascular inflammation or background uptake from the myocardium [36, 37]. Moreover, cardiac and respiratory movements, resulting in motion artifacts can significantly hamper the analysis the PET/CT images [38]. In another clinical trial evaluating the effect of atorvastatin, Lo et al. were able to show that atorvastatin treatment causes a significant decrease in plaque volume in forty human immunodeficiency virus (HIV)-infected patients, diagnosed with subclinical atherosclerosis, but no significant decrease in TBR values of the investigated aorta [39]. Additionally, predefined endpoints including coronary atherosclerotic plaque as assessed by CT angiography showed the same trend. In contrast to Boczar et al., who randomized 35 HIV positive patients into two groups, one group receiving 10 mg/day rosuvastatin for 6 months and the other group receiving standard HIV treatment. At baseline and after 6 months, TBRmax in the thoracic aorta was determined, which showed a significant decrease in the statin group with a P-value of 0.003 after treatment [40]. In a 2013 prospective multi-center trial, Tawakol et al. investigated whether high-dose statin treatment would result in greater reductions in plaque inflammation than low-dose statins, using [18F]FDG PET. Subjects with a high-risk profile or with proven atherosclerosis, who did not receive high-dose statins at the time of inclusion, were randomized in two treatment groups of atorvastatin with 10 mg versus 80 mg. [18F]FDG uptake in the ascending thoracic aorta and the carotid arteries was quantified by using TBR. Subjects were scanned at baseline as well as at 4 and 12 weeks after start of the treatment [21]. The 12-week statin therapy showed a significant decrease in [18F]FDG uptake in the analyzed arteries in the 80 mg group. In another prospective randomized investigator-blinded open-label study, the effects of two doses of atorvastatin on the incorporation of [18F]FDG into atherosclerotic plaques were investigated [41]. The study population comprised subjects with stable angina pectoris that were scheduled to undergo percutaneous coronary intervention (PCI). Subjects were randomly assigned to atorvastatin 5 mg or 20 mg a day for a 6 month period [41]. The day after PCI, the uptake of [18F]FDG in the ascending aorta and femoral artery was determined and measurements were repeated after 6 months. The overall reduction in TBR after 6 months of treatment was significant in both the ascending aorta and the femoral artery but only in the “20 mg/day atorvastatin” group. The conclusion of both studies is that [18F]FDG PET is able to depict a dose-dependent reduction of inflammation in patients receiving statin medication [21, 41]. In 2019, Oh et al. investigated the effects of the combination therapy ezetimibe and simvastatin 10/10 mg compared to monotherapy with rosuvastatin 10 mg on carotid atherosclerotic plaque inflammation [42]. Ezitimibe in combination with a low dose of statin is prescribed to minimize side effects of the statins. However, little is known whether this combination is as effective as powerful monotherapy with statins in reducing LDL cholesterol levels and diminishing atherosclerotic plaque inflammation. After we found that both ezetimibe/simvastatin 10/10 mg and rosuvastatin 10 mg resulted in a similar significant improvement of carotid atherosclerotic plaque inflammation in patients with carotid artery disease and acute coronary syndrome. It suggests that their anti-inflammatory effects are equivalent. Evolocumab is a recently introduced anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody that leads to a powerful reduction of LDL-c and lipoprotein (a) (Lp (a)) [43, 44]. Lp (a) may be associated as an independent and causal risk factor for the development of CVD [45, 46]. Lp (a) consists mainly of APO (a), which are found on the Lp (a) and covalently bound to LDL-C. The rationale why Lp (a) could be a risk factor for CVD is that this risk is partially driven by pro-inflammatory oxidized phospholipids, which are abundant on the APO-a tail of Lp (a) [47]. In a recently published RCT, 129 people in total were randomized to an evolocumab group (n = 65) and a placebo group (n = 64). A monthly subcutaneously injection of 420 mg evolocumab or of a placebo was started for 16 weeks. Arterial inflammation was assessed by [18F]FDG PET as a most diseased segments-TBR (MDS-TBR) of > 1.6 in an index vessel, left/right carotid or thoracic aorta. After 16 weeks of treatment no reduction in vascular inflammation was observed in the index vessel. However, independently from the imaging results, significant drops in LDL-C, HDL, triglycerides, total cholesterol and Lp (a) were seen [43, 44]. [18F]FDG PET in studies with anti-inflammatory drugs As already mentioned above, treatment with statins appears to deliver a beneficial anti-inflammatory effect in patients suffering from atherosclerosis. However, it is obvious, that despite the widespread use of statins, some patients still suffer not only from significant inflammatory changes in the arteries but also from an impaired cardiovascular outcome. Therefore, new therapeutic options that induce anti-inflammatory effects are clearly needed. Fayad et al. investigated the effect of Dalcetrapib, a cholesteryl ester transfer protein (CETP), on vessel inflammation in 64 patients. They hypothesized that the increase of high-density lipoprotein cholesterol (HDL-c) by Dalcetrapib could reduce atherosclerosis due to the well-known favorable effects of the “good” cholesterol HDL-c in contrast to the “bad” LDL. Despite its promising hypothesis, Dalcetrapib (when compared to placebo) did not result in a significant reduction of arterial inflammation by [18F]FDG-PET [23]. Dalcetrapib was associated with an improvement in only one of four co-primary magnetic resonance imaging (MRI) vascular endpoints, and, in the separate clinical endpoint trial, did not reduce adverse cardiovascular events in the patients included compared with placebo [23]. Another investigated drug is VIA-2291, a 5-LO-inhibitor. 5-LO is a key enzyme in the formation of leukotrienes, in special the potent chemoattractant leukotriene B4 (LTB4) that leads to inflammation. 5-LO-inhibitors were initially developed for the treatment of asthma, but were in this study 5-LO-inhibitors evaluated in the context of arterial inflammation. Forty-five subjects with recent acute coronary syndrome were included [48]. However, after 24 weeks of treatment no reduction in inflammation was observed in the index vessel alongside with no reduction in inflammatory parameters by means of [18F]FDG PET [49]. Trehalose, a natural disaccharide, which is hypothesized to reduce inflammation by boosting macrophage autophagic activity. This has been shown to mitigate the development of atherosclerotic plaque in different animal models that promote atherosclerosis. In Jamialahmadi’s 2022 study, 15 patients with a history of myocardial infarction were randomized into two groups, with one group receiving Trehalose and the other group receiving a placebo. After 12 weeks of intervention, the change in MDS-TBR of the index vessel was determined, which showed no significant reduction in arterial wall inflammation [50]. Recently, P38 mitogen-activated protein kinase inhibitors (P38MAPK) were studied in the context of arterial inflammation. Activation of P38MAPK leads to amplification of the inflammatory cascade through enhanced production of multiple cytokines [51]. P38MAPK-inhibitors such as losmapimod and BMS-582949 are selective, reversible, competitive inhibitors of P38MAPK [24, 25]. After 24 weeks of treatment with two different dosages of losmapimod amongst ninety-nine patients with a clinically stable history of atherosclerosis, vascular inflammation was assessed by [18F]FDG PET imaging of the carotid arteries and aorta. Analyses focused on the index vessel indicating the highest mean TBR. Losmapimod did not cause significant reduction in arterial inflammation, in the hypothesized primary endpoint [25]. However, in very specific high active segments MDS (TBR > 1.6) significance in reduction of vascular inflammation (p = 0.002) was found along with significant reduction in inflammatory parameters (p = 0.023) [25]. Emami et al. investigated a P38MAPK-inhibitor and its effect on vessel inflammation as compared to statin treatment with atorvastatin. Seventy-two subjects with documented atherosclerosis were included and randomized to the P38MAPK-inhibitor (100 mg once daily), placebo, or atorvastatin (80 mg once daily) for 12 weeks. Vascular inflammation was determined with [18F]FDG PET in the carotid arteries and aorta. It has been demonstrated that [18F]FDG PET resulted in a significant reduction in vascular inflammation. (p = 0.04) within the atorvastatin group supported by reduction in inflammatory parameters (p = 0.04). As with the losmapimod study, this effect was not seen in the P38MAPK-inhibitor group [24]. On the other hand, results of this study are in in line with previous studies showing the effectiveness of statins as already mentioned above. Tumor necrosis factor alpha (TNF-α) plays an important role in inflammation, for example seen in rheumatoid arthritis (RA) [52]. Anti-TNF-α reduces inflammation by inhibiting TNF-α and is commonly used in patients suffering from rheumatoid arthritis (RA). Mäki-Petäjä et al. evaluated whether anti-TNF-α was also able to reduce aortic inflammation [53]. In this study, aortic inflammation was quantified by [18F]FDG PET in 17 subjects with RA before and after 8 weeks of anti-TNF-α therapy. These 17 subjects were matched with 34 subjects with stable CVD as positive controls. Following 8 weeks of treatment with TNF-α, they indeed found a significant reduction of aortic [18F]FDG uptake (p = 0.03), supported by reduction in inflammatory parameters (p = 0.007). Bissonnette et al. investigated the anti-TNF-α drug adalimumab and its effect on vascular inflammation [54]. Thirty subjects with moderate to severe psoriasis and diagnosed with clinical atherosclerosis or with a high-risk profile for atherosclerosis were included. Subjects were randomized to receive either adalimumab subcutaneously for four months, or non-systemic treatment (topical therapies or phototherapy). Vascular inflammation was measured in the carotid artery and ascending aorta at baseline and week 15 using [18F]FDG PET. After four months of intervention, no demonstrable decrease in vascular inflammation between adalimumab and the control group could be shown. In contrast, a significant decrease in hs-CRP was indeed noticeable (p = 0.002) [54]. Secukinumab, a treatment for psoriasis, was assessed for its impact on vascular inflammation and biomarkers of cardiometabolic disease. The study by Gelfand et al. involved a 12-week randomized, placebo-controlled, double-blind treatment period, followed by 40 weeks of secukinumab treatment. The results showed that secukinumab had a neutral impact on aortic vascular inflammation and biomarkers of cardiometabolic disease after 52 weeks of treatment, with no significant changes observed in aortic inflammation or markers of advanced lipoprotein characterization, adiposity, or insulin resistance [55]. Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is an oral antidiabetic agent, which also yields favorable cardiovascular effects [56]. Studies have shown that DPP-4 inhibitors reduce the size of atherosclerotic plaques and macrophage accumulation [57]. Therefore, [18F]FDG PET was suggested to be capable in detecting reduction of arterial inflammation after administration of linagliptin. This has been studied by de Boer et al. in forty-five patients diagnosed with early type-2 diabetes mellitus [57]. TBRs in the linagliptin group showed a reduction at 26 weeks after intervention (p = 0.015), but no significance was found in the other evaluated inflammatory parameters. Expanding on the previous study, Ripa et al. published a study in 2021 which randomized 102 diabetic patients into two groups, with one group receiving liraglutide for 26 weeks and the other group receiving a placebo for the duration of the study [58]. After 26 weeks of treatment, there was no significant reduction observed in vascular inflammation. Two other oral anti-diabetic drugs, pioglitazone and glimepiride, were investigated regarding their potentially beneficial effect on arterial inflammation. One group looked at the effect of pioglitazone and glimepiride especially in the coronaries and the other group analyzed the aorta [59, 60]. In both studies, subjects with impaired glucose tolerance or diabetic patients with carotid atherosclerosis were included. They were randomly assigned to receive either pioglitazone (15 mg to 30 mg) or glimepiride (0.5 mg to 4.0 mg) for 4 months with titration to the optimum dose. At baseline and after 4 months of follow-up, subjects underwent a [18F]FDG PET/CT showing pioglitazone with a significant effect on arterial inflammation compared to glimepiride, which could be demonstrated both in the coronaries and in the aorta [59, 60]. Furthermore, imaging findings were supported by a significant decreased in hs-CRP. Discussion Over the last decades, [18F]FDG PET served as an end-point marker for several interventional trials by depicting arterial inflammation and by tracing the inflammatory process over a certain time period. This is due to the fact, that [18F]FDG PET can visualize, and also quantify, whether a certain medication has a favorable “anti-inflammatory” effect or not. As an additional benefit of atherosclerotic [18F]FDG PET imaging, it provides information if a reduction of inflammatory changes is i.e. seen in the entire vessel or restricted to specific areas within the artery such as hot spots potentially indicating inflammatory atherosclerotic plaques. Based on the data summarized in this review, a significant reduction in arterial inflammation can be observed after an intervention with statins [6, 19–21, 35, 39–42]. While statins have demonstrated anti-inflammatory effects, their primary mechanism targets lipid metabolism. This non-specific action may partially explain the moderate therapeutic effects observed in [18F]FDG PET studies. Strikingly, the majority of the [18F]FDG imaging data is supported by an accompanying significant reduction in “non-PET” parameters like LDL-c, total cholesterol and hs-CRP [61, 62]. [18F]FDG uptake reflects local inflammation, while hsCRP serves as a rather unspecific systemic marker for inflammatory disease burden. There is only one study by Lo et al. not showing a statin related reduction of arterial (aortic) inflammation as depicted by [18F]FDG PET [39]. The reason why the statin did not demonstrate a reduction in arterial inflammation in the aorta, despite its efficacy in deterring overall coronary plaque progression and inducing regression in noncalcified plaques among HIV-infected patients, could be attributed to the limitations in directly measuring arterial inflammation. Contrarily, in the vast majority of the analyzed studies, [18F]FDG PET provided detailed visualization of inflammation reduction; both in overall reduction or in specific high-uptake areas. However, various studies revealed that statins contribute to “only” a 30–40% coronary heart disease (CHD) reduction, quantified as the risk of non-fatal myocardial infarction (MI) or CHD death [10–12]. But, what at the end defines the effectiveness of statins, causing an improvement in cardiovascular risk? The primary reduction in LDL-cholesterol or the intrinsic anti-inflammatory capabilities of statins or both? Stiekema et al. observed that lowering LDL-C and Lp (a) using evolocumab has no effect on vascular inflammation [43]. This is an interesting finding because it, on the one hand, shows that solely lowering cholesterol seems not to reduce arterial inflammation on its own. On the other hand, it emphasizes the importance of the pleiotrophic anti-inflammatory and plaque-stabilizing capacities of statins leading to a reduction of arterial inflammation and, consequently, the risk of cardiovascular events [61–63]. Doubtlessly, statins cannot serve as a definitive, “stand alone”, conservative treatment against cardiovascular events, meaning that there is a clear need for additional/new approaches in the medical treatment of CVD [64]. With that regard, we also reviewed the role of [18F]FDG PET as an endpoint marker in studies evaluating “new” and promising anti-inflammatory drugs in atherosclerosis. For example, studies were published with patients in whom by intention HDL was increased by using newly developed medications, assuming a better ratio between HDL/LDL would lead to a reduction of the cardiovascular risk [23]. Unfortunately, the results were disappointing both from a clinical but also from imaging point of view with no significant difference between the placebo and the intervention group. Within the same period of time, various anti-inflammatory drugs such as Anti-TNF-α, mitogen-activated protein kinase (MAPK)-inhibitors, 5-LO inhibitors have also been investigated by using [18F]FDG PET [24, 25, 49, 54]. It was hypothesized that their mechanism of action would also affect the ongoing inflammatory process in atherosclerosis, yet results of the respective trials showed contrary results with primary endpoints frequently not being achieved. To, at least partly, elucidate those observations, the results of the recently published clinical CIRT and CANTOS trials need to be taken into account, even though they revealed contradictory results [52, 65, 66]. The CIRT trial (low dose methotrexate over four years) revealed no noticeable reduction in CV events. On the other hand, the CANTOS trial showed a significant reduction in CV events noticeable after a 4-year follow-up period after intervention with an human monoclonal antibody targeted at interleukin-1β (canakinumab) [48, 60–62, 66]. A small pilot [18F]PET study evaluating the impact of canakinumab suggests that this compound may also reduce arterial inflammation [67]. Accordingly, it is evident that anti-inflammatory drugs have inconsistently impacted arterial inflammation and CVD risk. While great promise remains for the use of anti-inflammatory drugs in CVD, more studies are needed in order to identify additional drugs that have an attractive cost to benefit ratio. Perhaps imaging arterial inflammation may contribute to the identification of such therapies. Limitations Limitations regarding [18F]FDG PET Limitations regarding the included publications are the small study population in the majority of the studies of which some target groups are in charge of a chronic disease, which might of course give a distorted picture of reality. However, previous studies, such as Rudd et al., have shown that small sample sizes can yield significant results in this type of research, emphasizing that the current methodology targets overall inflammatory activity rather than individual plaques [68]. One major limitation of the PET technique is quantifying the [18F]FDG uptake in a distinct vulnerable plaque. This remains a challenge in general, because the spatial resolution of the current PET-imaging systems is limited to approximately 3–4 mm [38]. All studies evaluated changes in the vessels based on multiple different arterial uptake parameters, such as whole vessel analysis or MDS. The use of these parameters is accepted to prevent or at least reduce the named limitations of a more direct analysis of a vulnerable plaque, like the partial volume effect. However, when looking at the coronary arteries, this approach is even more challenging or almost impossible by means of the PET technique. First of all, the small size of the coronaries, which is 3–4 mm, is hampering as it falls below the spatial resolution of the PET. In addition, the myocardium frequently shows a very high and varying physiological [18F]FDG uptake, making the differentiation between vascular inflammation or background uptake from the myocardium difficult [36, 37]. Moreover, motion artifacts during the scan due to cardiac and respiratory movements can significantly impair the analysis of the PET/CT images [38]. Finally, observed differences in the study results may also be based on differences in [18F]FDG PET protocols, encompassing variations in fasting duration, glucose cut-off points, dosage administration, and uptake periods as outlined in appendix C. Standardizing these procedural aspects is crucial for enhancing result comparability and reinforcing the reliability of conclusions drawn from [18F]FDG PET data. This imperative standardization could lead to improved reproducibility and facilitate meaningful cross-study comparisons, advancing a more cohesive understanding of metabolic activity in diverse study populations. Study level In this review, the majority of studies are RCTs. They are of decent quality and have little or at least reasonable bias in the areas for example bias due to deviations from intended interventions, bias due to missing outcome data achieved with the ROB-2 tool as seen in appendix D. Yet, multiple studies are funded by pharmaceutical industries, which per se causes high risk of bias. However, the most important types of bias for this review (detection, attrition, reporting-bias) are low leading to reliable results. Two included studies are open-label studies. The design of these two open-label studies is already a limitation, which means that the bias that occurs within these studies must be taken into account. To analyze these studies the ROBINS-I tool is being used. However, bias in measurement of outcomes and the bias in selection of the reported result are in both studies low. Therefore, the results/outcomes are reliable and relevant for this review. Review level By intention, no meta-analysis was performed when writing this review. This was due to the fact, that, although such a meta-analysis would be worthwhile, the diversity of the applied study protocols (both intervention- but also imaging protocols), the heterogeneity of the different study populations and the number of patients included in the analyzed studies would clearly hamper a robust meta-analysis of the data. It needs therefore to be doubted, that this shortcoming can be overcome in the future. Another limitation of this study is the fact that a language restriction was used in the process of data collection. Conclusions Numerous previously published studies used [18F]FDG PET as an endpoint marker in interventional trials in recent years. In this systematic review, we provide an overview of studies investigating the effectiveness of statins on the one hand and several new anti-inflammatory drugs on the other hand aiming to reduce arterial inflammation. The results emphasize three important findings. Firstly, statins indeed contribute to a significant reduction in arterial inflammation, accompanied by a significant reduction of the arterial [18F]FDG uptake. Secondly, using [18F]FDG PET as an endpoint marker, the ineffectiveness of different new anti-inflammatory drugs was confirmed. Finally, the value of [18F]FDG-PET to be a sufficient surrogate marker for both, positive as well as no relevant, effects of the respective drugs being evaluated is clearly supported by the included trials, in most cases by, but not only, other evaluated inflammatory and clinical parameters. Supplementary Information Supplementary Material 1 Acknowledgements Not applicable. Abbreviations [18F]Fluorodeoxyglucose-positron-emission-tomography 5-lipoxygenase- inhibitor Apolipoprotein type a Acetylsalicylic acid Atherosclerotic cardiovascular disease Coronary artery disease Cholesteryl ester transfer protein Coronary heart disease C-reactive protein Cardiovascular Cardiovascular disease Dipeptidyl peptidase-4 etcetera High dose High density lipoprotein/high density lipoprotein cholesterol Human immunodeficiency virus High-risk morphology High sensitive C-reactive protein Interleukin id est Low-density lipoprotein/low density lipoprotein cholesterol left main coronary artery Lipoprotein (a) Leukotriene B4 Mitogen-activated protein kinase Most diseased segments Medical Subject Headings Myocardial infarction Magnetic resonance imaging Oxidized LDL P38 Mitogen-activated Protein Kinase inhibitor Percutaneous coronary intervention Anti-proprotein converstase subtilisin/kexin type 9 Positron emission tomography Preferred Reporting Items for Systematic Reviews and Meta-Analyses Rheumatoid arthritis Randomized controlled trial Cochrane risk - of - bias tool - 2 Risk of Bias in Non – Randomized Studies or Interventions Region of interest Standard deviation Standardized uptake values Target-to-background ratio Tumor necrosis factor alpha Appendix Appendix A. Search strategy See Tables 1 and 2. Appendix B. A flow chart of the study selection See Tables 3, 4 and Figure 4. Appendix D. Quality assessment of the studies Bias assessment using the Cochrane Risk of Bias-2 (ROB-2) Tool for RCTs See Tables 5 and 6. Bias assessment using the ROBINS-I Tool for non-randomized studies Appendix E. Outcomes of the included studies See Table 7. Authors’ contributions All authors provided input in the concept of the review article. CEWG and JB drafted the report, which was critically reviewed by FMM, AT, and JEW. All authors approved the final version of the manuscript for submission. Further information on the contribution of each author is given in the online submission procedure. Funding Conflict of Interest: Authors FMM and JB received partial funding from European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 7226091. FMM is medical advisor for NanoMab Technology Ltd. and Advanced Accelerator Applications (AAA) GmbH/Novartis, holds speaker positions at Siemens, GE Healthcare and Bayer, and has recently received institutional grants from NanoMab Technology Ltd., Siemens and GE Precision Healthcare LLC. FMM is supported by the German Research Foundation (DFG) within the framework of the Research Training Group 2375 “Tumor-targeted Drug Delivery” (grant 331065168), the Clinical Research Unit CRU 5011 “Integrating emerging methods to advance translational kidney research (InteraKD)” (project 445703531), and the Research Unit 2591 “Severity assessment in animal-based research” (project 321137804). In addition, his research is funded by German Cancer Aid (projects 70113779 and 70113780) and the German Federal Ministry of Research and Education (project 16GW0319K). Furthermore, his work has been supported by an unrestricted grant from Nanomab Technology Ltd. None of the funding is related to the topics covered in the review. JB receives institutional funding from the International Atomic Energy Agency in the context of the “PIAF”-trial (core lab). Outside the submitted work. JB declares, that he is Associate Editor of European Journal of Nuclear Medicine and Molecular Imaging Research and in this position mainly responsible for topics related to cardiovascular research/submissions. JEW received institutional grants via Clinical Trial Center Maastricht from Bard, Bayer, Boston, Brainlab, GE, Philips, Siemens, and via the Speaker’s bureau via Maastricht UMC+ from Bayer and Siemens. All outside the submitted work. AT receives grant support from NIH, IAEA, Osler/Harvard, and Lung Biotech. None of the funding is related to the topics covered in the review. No further direct or indirect conflicts of interest or disclosures related to the content of this article have to be declared. Data availability The data underlying this article are available in the article and in its online supplementary material. The datasets underlying this article were derived from sources in the public domain and is available in PubMed: https://pubmed.ncbi.nlm.nih.gov/. Declarations Ethics approval and consent to participate Not applicable (This article does not contain any studies with human participants or animals performed by any of the authors). Consent for publication Not applicable. Competing interests Jan Bucerius is Associate Editor of the European Journal of Nuclear Medicine and Molecular Imaging Research and is Member of the Editorial Board of the European Journal of Nuclear Medicine and Molecular Imaging. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The data underlying this article are available in the article and in its online supplementary material. The datasets underlying this article were derived from sources in the public domain and is available in PubMed: https://pubmed.ncbi.nlm.nih.gov/.